CryoPort (NASDAQ:CYRX) CFO Robert Stefanovich Sells 9,300 Shares

CryoPort, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich sold 9,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $8.67, for a total transaction of $80,631.00. Following the completion of the sale, the chief financial officer directly owned 207,213 shares in the company, valued at approximately $1,796,536.71. This trade represents a 4.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

CryoPort Stock Performance

NASDAQ CYRX opened at $8.97 on Friday. The company’s 50 day moving average is $7.63 and its 200-day moving average is $6.65. CryoPort, Inc. has a 12-month low of $4.58 and a 12-month high of $9.48. The company has a quick ratio of 15.47, a current ratio of 16.24 and a debt-to-equity ratio of 0.39. The firm has a market cap of $449.13 million, a P/E ratio of 6.74 and a beta of 1.88.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.09). CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. The business had revenue of $45.45 million during the quarter, compared to the consensus estimate of $41.74 million. CryoPort has set its FY 2025 guidance at EPS. Sell-side analysts predict that CryoPort, Inc. will post -0.99 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on CYRX shares. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of CryoPort in a research report on Thursday, May 8th. KeyCorp upgraded CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 price target on the stock in a research report on Wednesday, August 6th. Leerink Partnrs upgraded CryoPort from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 6th. BTIG Research decreased their price target on CryoPort from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, July 7th. Finally, Morgan Stanley decreased their price target on CryoPort from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Monday, May 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $12.00.

Institutional Trading of CryoPort

Several hedge funds and other institutional investors have recently bought and sold shares of CYRX. JPMorgan Chase & Co. boosted its stake in CryoPort by 10.8% in the fourth quarter. JPMorgan Chase & Co. now owns 338,315 shares of the company’s stock worth $2,632,000 after buying an additional 33,078 shares in the last quarter. Wells Fargo & Company MN boosted its stake in CryoPort by 29.4% in the fourth quarter. Wells Fargo & Company MN now owns 28,767 shares of the company’s stock worth $224,000 after buying an additional 6,533 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in CryoPort by 135.5% in the fourth quarter. Russell Investments Group Ltd. now owns 12,875 shares of the company’s stock worth $100,000 after buying an additional 7,407 shares in the last quarter. Invesco Ltd. boosted its stake in CryoPort by 11.6% in the fourth quarter. Invesco Ltd. now owns 51,803 shares of the company’s stock worth $403,000 after buying an additional 5,364 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in CryoPort in the fourth quarter worth approximately $194,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.